Abstracts tagged "FMRI"

Abstract Number: 2024 • 2017 ACR/ARHP Annual Meeting
Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain – an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial
Hannah Schenker¹, Andreas Hess², Laura Konerth², Marina Sergeeva², Jutta Prade², Arnd Kleyer¹, Michaela Reiser¹, Axel J. Hueber¹, Matthias Englbrecht¹, Eugen Feist³, Reinhard Voll⁴, Bettina Bannert⁴, C Baerwald⁵, Julie Rösch⁶, Arnd Dörfler⁷, José António P. da Silva⁸, Nemanja Damjanov⁹, Georg Schett¹ and Juergen Rech¹, ¹Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Institute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Rheumatology and Clinical Immunology, Charité, Berlin, Berlin, Germany, ⁴Clinic for Rheumatology and Clinical Immunology, Medical University of Freiburg, Germany, Freiburg, Germany, ⁵Department of Rheumatology, University of Leipzig, Germany, Leipzig, Germany, ⁶Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, Erlangen, Germany, ⁷Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, e, Germany, ⁸Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁹Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) signify a major advance in the treatment of rheumatoid arthritis (RA). However, treatment success initially remains uncertain as one…
Abstract Number: 1981 • 2016 ACR/ARHP Annual Meeting
A Pilot Pulsed Arterial Spin Labeling Study of Regional Cerebral Blood Flow in Response to Pain in RA, before and after DMARD Treatment
Yvonne C. Lee¹, Alexander Fine², Ekaterina Protsenko³, Elena Massarotti⁴, Robert R. Edwards⁵, Vitaly Napadow⁶ and Marco Loggia³, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ⁵Anesthesiology, Brigham & Womens Hospital, Chestnut Hill, MA, ⁶Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA
Background/Purpose: Although significant advances have been made in treating inflammation in RA, little is known about central nervous system (CNS) pain pathways in inflammatory arthritis.…
Abstract Number: 1019 • 2015 ACR/ARHP Annual Meeting
Brain Functional Connectivity Differentially Predicts Response to Two Centrally Acting Analgesics in Fibromyalgia
Eric Ichesco¹, Johnson Hampson², Lynne Pauer³, Andrew Clair⁴, Tobias Schmidt-Wilcke⁵, David A. Williams⁶, Daniel J. Clauw² and Richard E. Harris¹, ¹Anesthesiology, U. Michigan, Ann Arbor, MI, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Pfizer Inc, New London, CT, ⁴Pfizer Inc., New York, NY, ⁵Bergmannsheil, Bochum, Germany, ⁶Anesthseiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Recently, several functional brain imaging techniques including functional magnetic resonance imaging (fMRI) have been proposed to be useful in probing the mechanisms of action…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].